The company met our estimates on revenue front and outperformed by 3%/9% on EBITDA and PAT front for FY24.The outperformance we believe was on the back of strong show in the US and Emerging and Europe markets, improved products mix, lower input costs, improved gross margins in Consumer Wellness and improved price realizations.